

Pier Leopoldo Capecchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/967457/publications.pdf>

Version: 2024-02-01

51
papers

2,017
citations

331670

21
h-index

243625

44
g-index

51
all docs

51
docs citations

51
times ranked

2688
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19, Arrhythmic Risk, and Inflammation. <i>Circulation</i> , 2020, 142, 7-9.	1.6	219
2	Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. <i>European Heart Journal</i> , 2017, 38, ehw208.	2.2	203
3	Long QT Syndrome: An Emerging Role for Inflammation and Immunity. <i>Frontiers in Cardiovascular Medicine</i> , 2015, 2, 26.	2.4	133
4	Worldwide Survey of COVID-19-Associated Arrhythmias. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009458.	4.8	127
5	Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. <i>Nature Reviews Immunology</i> , 2019, 19, 63-64.	22.7	108
6	Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation. <i>PLoS ONE</i> , 2018, 13, e0208321.	2.5	105
7	Systemic Inflammation Rapidly Induces Reversible Atrial Electrical Remodeling: The Role of Interleukin-6-Mediated Changes in Connexin Expression. <i>Journal of the American Heart Association</i> , 2019, 8, e011006.	3.7	94
8	Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes. <i>Heart</i> , 2017, 103, 1821-1829.	2.9	90
9	Antiarrhythmic Potential of Anticytokine Therapy in Rheumatoid Arthritis: Tocilizumab Reduces Corrected QT Interval by Controlling Systemic Inflammation. <i>Arthritis Care and Research</i> , 2015, 67, 332-339.	3.4	85
10	Autoimmune channelopathies as a novel mechanism in cardiac arrhythmias. <i>Nature Reviews Cardiology</i> , 2017, 14, 521-535.	13.7	82
11	COVID-19 Sepsis and Microcirculation Dysfunction. <i>Frontiers in Physiology</i> , 2020, 11, 747.	2.8	79
12	Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. <i>Autoimmunity Reviews</i> , 2014, 13, 936-944.	5.8	75
13	Emerging Arrhythmic Risk of Autoimmune and Inflammatory Cardiac Channelopathies. <i>Journal of the American Heart Association</i> , 2018, 7, e010595.	3.7	72
14	Arrhythmogenicity of Anti-Ro/SSA Antibodies in Patients With Torsades de Pointes. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e003419.	4.8	55
15	Cardiac Arrest Risk During Acute Infections. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008627.	4.8	44
16	Upregulation of A2A adenosine receptor expression by TNF- α in PBMC of patients with CHF: a regulatory mechanism of inflammation. <i>Journal of Cardiac Failure</i> , 2005, 11, 67-73.	1.7	34
17	The role of P2X7 receptors in tissue fibrosis: a brief review. <i>Purinergic Signalling</i> , 2015, 11, 435-440.	2.2	33
18	Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19. <i>Nature Reviews Immunology</i> , 2022, 22, 270-272.	22.7	32

#	ARTICLE	IF	CITATIONS
19	Isolated atrioventricular block of unknown origin in adults and anti-Ro/SSA antibodies: Clinical evidence, putative mechanisms, and therapeutic implications. <i>Heart Rhythm</i> , 2015, 12, 449-454.	0.7	27
20	Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1958-65.	2.0	24
21	Potassium Channel Block and Novel Autoimmune-Associated Long QT Syndrome. <i>Cardiac Electrophysiology Clinics</i> , 2016, 8, 373-384.	1.7	22
22	Marked QTc Prolongation and Torsades de pointes in Patients with Chronic Inflammatory Arthritis. <i>Frontiers in Cardiovascular Medicine</i> , 2016, 3, 31.	2.4	20
23	Autoimmune and inflammatory K ⁺ channelopathies in cardiac arrhythmias: Clinical evidence and molecular mechanisms. <i>Heart Rhythm</i> , 2019, 16, 1273-1280.	0.7	18
24	Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3083-3098.	4.3	17
25	Autoimmune Calcium Channelopathies and Cardiac Electrical Abnormalities. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 54.	2.4	17
26	IL-6 (Interleukin 6) Blockade and Heart Rate Corrected QT Interval Prolongation in COVID-19. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008791.	4.8	17
27	Clinically-relevant cyclosporin and rapamycin concentrations enhance regulatory T cell function to a similar extent but with different mechanisms: An in-vitro study in healthy humans. <i>International Immunopharmacology</i> , 2015, 24, 276-284.	3.8	15
28	Antirheumatic agents in covid-19: is IL-6 the right target?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e2-e2.	0.9	15
29	Isolated atrioventricular block of unknown origin in the adult and autoimmunity: diagnostic and therapeutic considerations exemplified by 3 anti-Ro/SSA-associated cases. <i>HeartRhythm Case Reports</i> , 2015, 1, 293-299.	0.4	14
30	Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad. <i>Immunologic Research</i> , 2017, 65, 262-275.	2.9	14
31	Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes. <i>Frontiers in Pharmacology</i> , 2020, 11, 684.	3.5	13
32	Comment on "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?": <i>Journal of Hepatology</i> , 2021, 75, 994-995.	3.7	11
33	Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases. <i>Scientific Reports</i> , 2022, 12, 1075.	3.3	11
34	Torsades de Pointes in Patients with Polymyalgia Rheumatica. <i>Current Pharmaceutical Design</i> , 2018, 24, 323-340.	1.9	10
35	Unravelling Atrioventricular Block Risk in Inflammatory Diseases: Systemic Inflammation Acutely Delays Atrioventricular Conduction via a Cytokine-Mediated Inhibition of Connexin43 Expression. <i>Journal of the American Heart Association</i> , 2021, 10, e022095.	3.7	10
36	Assessing QT interval in patients with autoimmune chronic inflammatory diseases: perils and pitfalls. <i>Lupus Science and Medicine</i> , 2016, 3, e000189.	2.7	9

#	ARTICLE	IF	CITATIONS
37	Proton Pump Inhibitors Directly Block hERG-Potassium Channel and Independently Increase the Risk of QTc Prolongation in a Large Cohort of US Veterans. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e010042.	4.8	8
38	Anti-Ro/SSA Antibodies and the Autoimmune Long-QT Syndrome. <i>Frontiers in Medicine</i> , 2021, 8, 730161.	2.6	8
39	Comment on "Absence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: A multicenter study of 689 patients" Seminars in Arthritis and Rheumatism, 2015, 44, e16-e17.	3.4	7
40	Cyclosporin and tacrolimus increase plasma levels of adenosine in kidney transplanted patients. <i>Transplant International</i> , 2005, 18, 289-295.	1.6	6
41	Commentary: Systemic effects of IL-17 in inflammatory arthritis. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 183.	2.4	6
42	Drug-Associated QTc Prolongation in Geriatric Hospitalized Patients: A Cross-Sectional Study in Internal Medicine. <i>Drugs - Real World Outcomes</i> , 2021, 8, 325-335.	1.6	6
43	Transient Hypogonadism Is Associated With Heart Rate-Corrected QT Prolongation and Torsades de Pointes Risk During Active Systemic Inflammation in Men. <i>Journal of the American Heart Association</i> , 2022, 11, e023371.	3.7	6
44	Autoimmune cardiac channelopathies: the heart of the matter. <i>Nature Reviews Cardiology</i> , 2017, 14, 566-566.	13.7	4
45	Inflammatory cytokines, life-threatening arrhythmias and premature mortality in chronic inflammatory arthritis: time to focus on. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e98-e98.	0.9	4
46	Adenosine receptors expression in cardiac fibroblasts of patients with left ventricular dysfunction due to valvular disease. <i>Journal of Receptor and Signal Transduction Research</i> , 2017, 37, 283-289.	2.5	3
47	Anti-Ca ^v 1.2 Antibody-Induced Atrioventricular Block as a Novel Form in the Adult: Long-Term Pacemaker-Sparing Activity of Hydroxychloroquine. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, .	4.8	2
48	Targeting IL-6 in COVID-19. Response to: "Rational use of tocilizumab in COVID-19" by Jain and Sharma. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-218627.	0.9	1
49	Letter by Lazzerini et al Regarding Article, "Autoantibody Signature in Cardiac Arrest" <i>Circulation</i> , 2020, 142, e370-e371.	1.6	1
50	Epidemiological and virological surveillance of Severe Acute Respiratory Infections in the 2019/2020 season in Siena, Tuscany, Italy.. <i>Journal of Preventive Medicine and Hygiene</i> , 2021, 62, E782-E788.	0.9	1
51	Surveillance for Severe Acute Respiratory Infections among Hospitalized Subjects from 2015/2016 to 2019/2020 Seasons in Tuscany, Italy. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3875.	2.6	0